PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug Impacted	**CRITERIA CHANGE**	**EFFECTIVE DATE**	**Formulary**
Sogroya	1) Updated criteria to include indications for small for gestational age (SGA), Noonan syndrome (NS), and idiopathic short stature (ISS) per FDA label update. 2) Expanded growth chart documentation to include chart notes or medical record documentation.	05/25/2026	Standard and Essential
Keytruda	For biliary tract cancer neoadjuvant treatment, added option in combination with carboplatin per NCCN. For hepatocellular carcinoma, updated criteria for single agent subsequent therapy per NCCN. For vulvar cancer, added requirement that single agent therapy is subsequent per NCCN. For RCC first-line, added coverage as single agent per Lexi-Drugs. For subsequent therapy, removed requirement for clear cell histology per NCCN. For cutaneous squamous cell carcinoma, added coverage for satellitosis/in-transit metastasis per NCCN. For soft tissue sarcoma, added coverage for neoadjuvant and adjuvant therapy for UPS related sarcomas, per NCCN. For soft tissue sarcoma, added clinical settings for subsequent treatment and 'pleomorphic' rhabdomyosarcoma per NCCN. For breast cancer, added coverage for use in combination with sacituzumab govitecan-hziy in members with no response to preoperative systemic therapy or for recurrent unresectable or metastatic TNBC, per NCCN. For PD-L1 positive breast cancer, specified CPS 10 or greater and removed single agent use per NCCN. For prostate cancer, removed requirement for subsequent treatment and removed coverage of MSI-H/dMMR disease. For Kaposi sarcoma, added criteria for advanced disease per NCCN. For vaginal cancer in combination with chemotherapy, added requirement for PD-L1 positive disease per NCCN. Removed criteria for TMB-H disease per NCCN. For penial cancer, added requirement for first-line therapy when used with chemotherapy per NCCN.	06/08/2026	Essential and Metallic

	Added coverage for chordoma per NCCN.		
Tafinlar	For pancreatic adenocarcinoma, expanded coverage for use as first line therapy for metastatic disease, per NCCN.	06/08/2025	Standard, Essential and Metallic
Mekinist	For pancreatic adenocarcinoma, expanded coverage for use as first line therapy for metastatic disease, per NCCN. For gastric, esophageal, and esophagogastric junction cancer, aligned line of therapy to from "palliative treatment" to "subsequent treatment", per NCCN.	06/08/2026	Standard, Essential and Exchange
Spravato	Removed documentation requirements related to prior treatment history. Updated Prescriber Specialty by removing 'prescribed by or in consultation with a psychiatrist' and adding REMS program requirements.	05/24/2026	Essential and Metallic